REDWOOD CITY, CA--(Marketwire - September 09, 2009) - Facet Biotech Corporation (NASDAQ: FACT)
today announced the election of Hoyoung Huh, M.D, Ph.D. as a member of its
board of directors effective September 5, 2009.
"We are pleased to have Hoyoung, a biotechnology industry leader with
extensive executive leadership, operating and business development
experience, join the Facet Biotech board," said Brad Goodwin, chairperson
of Facet Biotech's board of directors. "His broad, relevant knowledge of
our industry will be invaluable in helping us shape Facet into a leading
oncology-focused biotechnology company."
Dr. Huh is currently president and chief executive officer of BiPar
Sciences, Inc., a leading oncology therapeutics company and pioneer in the
novel mechanism of DNA-repair inhibition. BiPar has recently been acquired
by the global pharmaceutical company, sanofi-aventis, in April of 2009, and
remains as a center of innovation within sanofi-aventis. Prior to BiPar,
Dr. Huh served at Nektar Therapeutics, Inc., as a member of its board of
directors, chief operating officer and head of the PEGylation Business
Unit. Dr. Huh has led multiple partnerships with major pharmaceutical
companies, including Bayer AG, Baxter International Inc., Bristol-Myers
Squibb Co., Novartis AG, Pfizer, Inc and Roche Holding Ltd. Dr. Huh is a
thought leader and frequent speaker on topics including technology
licensing, mergers and acquisitions, and innovative product launches. He
was a partner at McKinsey & Company, a global management consulting firm,
where he served as a leader in the healthcare and biotechnology practice
across U.S., Europe and Asia. He currently serves on the board of directors
at BayBio, a biotechnology industry association, Interplast, Inc. and
SciDose LLC. Dr. Huh received his M.D. degree from Cornell University,
Ph.D. in Genetics/Cell Biology from Cornell University/Sloan-Kettering
Institute, and his A.B. in Biochemistry from Dartmouth College.
About Facet Biotech
Facet Biotech is a biotechnology company dedicated to advancing its
pipeline of five clinical-stage products, leveraging its research and
development capabilities to identify and develop new oncology drugs and
applying its proprietary next-generation protein engineering technologies
to potentially improve the clinical performance of protein therapeutics.
Facet Biotech Corporation launched in December 2008 as a spin-off from PDL
NOTE: Facet Biotech and the Facet Biotech logo are considered trademarks of
Facet Biotech Corporation.